My Cart

Activin RIIB

Activin RIIB Overview

English NameActivin receptor type-2BApproved Drugs0
Drugs in Clinical Trials6Target SynonymEC:2.7.11.30,EC 2.7.11,Activin receptor type IIB,ACVR2B,Activin A Receptor Type 2B,Activin A Receptor, Type IIB,Activin Receptor Type-2B,EC 2.7.11.30,ActR-IIB,ACTRIIB,HTX4
Highest Development StagePhase 2 Clinical
English NameActivin receptor type-2B
Target SynonymEC:2.7.11.30,EC 2.7.11,Activin receptor type IIB,ACVR2B,Activin A Receptor Type 2B,Activin A Receptor, Type IIB,Activin Receptor Type-2B,EC 2.7.11.30,ActR-IIB,ACTRIIB,HTX4
Approved Drugs0
Drugs in Clinical Trials6
Highest Development StagePhase 2 Clinical

Activin RIIB Background

Activin receptor type-2B (ACVR2B) is also known as ActR-IIB and MGC116908, ACVR2B is an activin type 2 receptor. Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. Defects in ACVR2B are the cause of visceral heterotaxy autosomal type 4 (HTX4).

Activin RIIB Synonyms

ACVR2B,ACTRIIB,MGC116908

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
BimagrumabLY-3985863; BYM-338Phase 2 ClinicalMorphosys Ag, Novartis Pharma AgDiabetes Mellitus, Type 2; Myositis, Inclusion Body; Obesity; Overweight; Pulmonary Disease, Chronic Obstructive; Sarcopenia
Details
BIIB-110BIIB-110; BIIB110; ALG-801Phase 1 ClinicalAlivegen USA IncMuscular Atrophy, Spinal; Muscular Diseases
Details
LAE-103LAE-103; LAE103Phase 1 ClinicalLaekna Therapeutics Shanghai Co LtdMuscular Diseases; Muscular Disorders, Atrophic; Obesity; Sarcopenia
Details
SSS-67SSS67; SSS-67Phase 1 ClinicalShenyang Sunshine Pharmaceutical Co LtdObesity; Overweight
Details
JMT-206JMT206; JMT-206Phase 1 ClinicalShanghai Jmt-Bio IncBody Weight; Obesity; Overweight; Sarcopenia
Details
Tirzepatide/BimagrumabLY-900042Phase 1 ClinicalEli Lilly And Company
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland